Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

yohimbine/rasvumus

Link salvestatakse lõikelauale
ArtiklidKliinilistes uuringutesPatendid
Leht 1 alates 48 tulemused
Low caloric diet is a commonly accepted treatment in obesity. However, owing to moderate results, a pharmacological support has been proposed. As some efficacious drugs activate overall sympathetic activity, they might modify functions of the cardiovascular system. Three groups of subjects were
The search for drugs with anorectic activity, acting within the adrenergic system has attracted the interest of researchers. Partial α2-adrenoceptor agonists might offer the potential for effective and safe treatment of obesity. We compared the effectiveness and safety of α2-adrenoceptor ligands in

Yohimbine and rauwolscine reduce food intake of genetically obese (obob) and lean mice.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Multiple behavioral and neurochemical abnormalities are found in the genetically obese mouse, obob , including hyperphagia, elevated hypothalamic norepinephrine (NE) levels, and increases alpha-1 receptor density. The obese mutant also responds abnormally to neuropharmacological agents. In the

Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Oral yohimbine administration (0.2 mg/kg) induced lipid mobilization (increase in plasma non-esterified fatty acids, NEFA) in fasting non-obese women (body mass index BMI = 20.2 +/- 0.5, age 35.5 +/- 2.7 years) without significant action on plasma glucose, insulin levels, heart rate or blood
The effect of ephedrine, a non-selective adrenoreceptor agonist, and yohimbine, a selective alpha 2-adrenolytic drug, on gastric emptying of a radiolabelled solid meal was examined in groups of 8 (all women) and 15 (4 men and 11 women) obese patients, respectively. Patients were given orally,
An anorectic drug, dexfenfluramine (dF) is commonly used in obesity treatment. The aim of our study was to investigate if dexfenfluramine used alone or together with alpha 2-adrenolitic yohimbine (Y), can change cardiovascular state in obese women.

[Evaluation of the effect of yohimbine, an alpha2 adrenolytic drug, on gastric emptying in obesity].

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In 15 obese subjects (11 women and 4 men) the effect was assessed of yohimbine, an alpha 2-adrenolytic drug on gastric emptying after solid food. After oral administration of 15 mg of the drug no significant change was observed in this emptying in relation to placebo.

[Lack of efficacy of yohimbine in the treatment of obesity].

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
There is some evidence that blockade of alpha 2-adrenoceptors on adipocytes may lead to an increase in lipolysis, We have therefore carried out a double blind comparative study of the effects of the selective alpha 2-antagonist yohimbine in human obesity. Nineteen obese volunteers participated in

Yohimbine attenuates clonidine-induced feeding and macronutrient selection in genetically obese (ob/ob) mice.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Biochemical abnormalities in the hypothalamus of the genetically obese (C57B1/6J, ob/ob) mouse, including increased levels of endogenous norepinephrine (NE) in the paraventricular nucleus (PVN) and reduced medial hypothalamic NE metabolism, have been cited as evidence of a CNS defect contributing to

[Use of yohimbine, an alpha-adrenolytic drug, in obesity].

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse

Neuropeptide Y in obese women during treatment with adrenergic modulation drugs.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND The aim of the study is the assessment whether weight loss treatment with adrenergic modulation drugs modifies neuropeptide Y (NPY) plasma concentration in obese women. METHODS 13 obese women (BMI 38.3 +/- 4.4) were tested before and subsequently 10 and 20 days after weight loss

Regional differences in adrenoceptor binding and fat cell lipolysis in obese, postmenopausal women.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In women there is an increase in visceral obesity, subcutaneous abdominal adipocyte lipolysis, and risk of cardiovascular disease (CVD) associated with weight gain after menopause. The mechanisms underlying this increase in adrenoreceptor (AR)-agonist catecholamine-stimulated lipolysis and abdominal
As compared to subcutaneous adipocytes, visceral adipocytes have high basal lipolysis, are highly sensitive to catecholamines, and are poorly sensitive to insulin; these traits are amplified when visceral adipocytes hypertrophy. As a result, enlarged visceral fat stores tend to flood the portal
We performed this study to investigate whether alpha- and beta-adrenergic agonists are able to regulate intracellular free magnesium concentrations [Mg2+]i in platelets from healthy and obese individuals. Twenty-six informed-consent men (14 healthy and 12 obese) were enrolled in the study. We
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge